<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font3" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font4" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="2" family="AkzidenzGroteskBE" color="#ffffff"/>
	<fontspec id="font6" size="15" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font7" size="16" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="12" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font9" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font10" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font11" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font12" size="9" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font13" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font14" size="9" family="Symbol" color="#000000"/>
	<fontspec id="font15" size="8" family="Symbol" color="#000000"/>
<text top="85" left="477" width="78" height="10" font="font0" id="p1_t1" reading_order_no="1" segment_no="1" tag_type="title">Open Access<a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="42" left="306" width="250" height="7" font="font1" id="p1_t2" reading_order_no="0" segment_no="0" tag_type="text">Available online http://breast-cancer-research.com/content/7/6/R1141<b>Available online</b></text>
<text top="735" left="569" width="23" height="8" font="font4" id="p1_t3" reading_order_no="74" segment_no="27" tag_type="text">R1141</text>
<text top="85" left="57" width="9" height="2" font="font5" id="p1_t4" reading_order_no="3" segment_no="2" tag_type="title">Vol 7 No 6</text>
<text top="85" left="57" width="103" height="14" font="font6" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="title">Research article</text>
<text top="102" left="57" width="485" height="14" font="font7" id="p1_t6" reading_order_no="4" segment_no="3" tag_type="title">Preclinical evaluation of transcriptional targeting strategies for</text>
<text top="120" left="57" width="414" height="14" font="font7" id="p1_t7" reading_order_no="5" segment_no="3" tag_type="title">carcinoma of the breast in a tissue slice model system<b>Preclinical evaluation of transcriptional targeting strategies for </b></text>
<text top="137" left="57" width="483" height="12" font="font8" id="p1_t8" reading_order_no="6" segment_no="4" tag_type="text">Mariam A Stoff-Khalili 2 , Alexander Stoff 1,3 , Angel A Rivera 1 , Nilam S Banerjee 4 , Maaike Everts 1 ,<b>carcinoma of the breast in a tissue slice model system</b></text>
<text top="153" left="57" width="482" height="12" font="font8" id="p1_t9" reading_order_no="7" segment_no="4" tag_type="text">Scott Young 5 , Gene P Siegal 5 , Dirk F Richter 3 , Minghui Wang 1 , Peter Dall 2 , J Michael Mathis 6 ,</text>
<text top="169" left="57" width="168" height="12" font="font8" id="p1_t10" reading_order_no="8" segment_no="4" tag_type="text">Zeng B Zhu 1 and David T Curiel 1</text>
<text top="203" left="57" width="499" height="7" font="font3" id="p1_t11" reading_order_no="9" segment_no="5" tag_type="text">1 Division of Human Gene Therapy, Departments of Medicine, Surgery, Pathology and the Gene Therapy Center, University of Alabama at Birmingham,</text>
<text top="213" left="57" width="116" height="7" font="font3" id="p1_t12" reading_order_no="10" segment_no="5" tag_type="text">Birminham, AL 35294-2172, USA</text>
<text top="222" left="57" width="398" height="7" font="font3" id="p1_t13" reading_order_no="11" segment_no="6" tag_type="text">2 Department of Obstetrics and Gynecology, University of Duesseldorf, Medical Center, 40225 Duesseldorf, Germany</text>
<text top="231" left="57" width="354" height="8" font="font3" id="p1_t14" reading_order_no="12" segment_no="7" tag_type="text">3 Department of Plastic and Reconstructive Surgery, Dreifaltigkeits-Hospital, 50389 Wesseling, Germany</text>
<text top="241" left="57" width="434" height="7" font="font3" id="p1_t15" reading_order_no="13" segment_no="8" tag_type="text">4 Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294-2172, USA</text>
<text top="250" left="57" width="499" height="8" font="font3" id="p1_t16" reading_order_no="14" segment_no="9" tag_type="text">5 Department of Pathology, Cellular Biology, and Surgery and the Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL 35294-</text>
<text top="260" left="57" width="39" height="7" font="font3" id="p1_t17" reading_order_no="15" segment_no="9" tag_type="text">2172, USA</text>
<text top="269" left="57" width="429" height="8" font="font3" id="p1_t18" reading_order_no="16" segment_no="10" tag_type="text">6 Department of Cellular Biology and Anatomy, Louisiana State University Health Sciences Center, Shreveport, LA 71130, USA</text>
<text top="288" left="57" width="184" height="7" font="font3" id="p1_t19" reading_order_no="17" segment_no="11" tag_type="text">Corresponding author: David T Curiel, curiel@uab.edu</text>
<text top="306" left="57" width="495" height="7" font="font3" id="p1_t20" reading_order_no="18" segment_no="12" tag_type="text">Received: 31 May 2005 Revisions requested: 12 Jul 2005 Revisions received: 25 Sep 2005 Accepted: 18 Oct 2005 Published: 16 Nov 2005</text>
<text top="324" left="57" width="252" height="7" font="font10" id="p1_t21" reading_order_no="19" segment_no="13" tag_type="text">Breast Cancer Research 2005, 7 :R1141-R1152 (DOI 10.1186/bcr1353)</text>
<text top="334" left="57" width="265" height="7" font="font3" id="p1_t22" reading_order_no="20" segment_no="14" tag_type="text">This article is online at: http://breast-cancer-research.com/content/7/6/R1141</text>
<text top="344" left="57" width="192" height="7" font="font3" id="p1_t23" reading_order_no="21" segment_no="15" tag_type="text">© 2005 Stoff-Khalili et al .; licensee BioMed Central Ltd.</text>
<text top="354" left="57" width="500" height="7" font="font3" id="p1_t24" reading_order_no="22" segment_no="16" tag_type="text">This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),</text>
<text top="364" left="57" width="409" height="7" font="font3" id="p1_t25" reading_order_no="23" segment_no="16" tag_type="text">which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</text>
<text top="384" left="57" width="43" height="10" font="font11" id="p1_t26" reading_order_no="24" segment_no="17" tag_type="title">Abstract</text>
<text top="404" left="57" width="240" height="8" font="font12" id="p1_t27" reading_order_no="25" segment_no="18" tag_type="text">Introduction In view of the limited success of available</text>
<text top="415" left="57" width="240" height="8" font="font13" id="p1_t28" reading_order_no="26" segment_no="18" tag_type="text">treatment modalities for metastatic breast cancer, alternative</text>
<text top="425" left="57" width="240" height="8" font="font13" id="p1_t29" reading_order_no="27" segment_no="18" tag_type="text">and complementary strategies need to be developed.</text>
<text top="436" left="57" width="240" height="8" font="font13" id="p1_t30" reading_order_no="28" segment_no="18" tag_type="text">Adenoviral vector mediated strategies for breast cancer gene</text>
<text top="446" left="57" width="240" height="8" font="font13" id="p1_t31" reading_order_no="29" segment_no="18" tag_type="text">therapy and virotherapy are a promising novel therapeutic</text>
<text top="457" left="57" width="240" height="8" font="font13" id="p1_t32" reading_order_no="30" segment_no="18" tag_type="text">platform for the treatment of breast cancer. However, the</text>
<text top="467" left="57" width="240" height="8" font="font13" id="p1_t33" reading_order_no="31" segment_no="18" tag_type="text">promiscuous tropism of adenoviruses (Ads) is a major concern.</text>
<text top="478" left="57" width="240" height="8" font="font13" id="p1_t34" reading_order_no="32" segment_no="18" tag_type="text">Employing tissue specific promoters (TSPs) to restrict</text>
<text top="488" left="57" width="240" height="8" font="font13" id="p1_t35" reading_order_no="33" segment_no="18" tag_type="text">transgene expression or viral replication is an effective way to</text>
<text top="499" left="57" width="240" height="8" font="font13" id="p1_t36" reading_order_no="34" segment_no="18" tag_type="text">increase specificity towards tumor tissues and to reduce</text>
<text top="509" left="57" width="240" height="8" font="font13" id="p1_t37" reading_order_no="35" segment_no="18" tag_type="text">adverse effects in non-target tissues such as the liver. In this</text>
<text top="520" left="57" width="240" height="8" font="font13" id="p1_t38" reading_order_no="36" segment_no="18" tag_type="text">regard, candidate breast cancer TSPs include promoters of the</text>
<text top="530" left="57" width="240" height="8" font="font13" id="p1_t39" reading_order_no="37" segment_no="18" tag_type="text">genes for the epithelial glycoprotein 2 (EGP-2),</text>
<text top="538" left="57" width="241" height="12" font="font13" id="p1_t40" reading_order_no="38" segment_no="18" tag_type="text">cyclooxygenase-2 (Cox-2), α -chemokine SDF-1 receptor</text>
<text top="551" left="57" width="240" height="8" font="font13" id="p1_t41" reading_order_no="39" segment_no="18" tag_type="text">(stromal-cell-derived factor, CXCR4), secretory leukoprotease</text>
<text top="562" left="57" width="106" height="8" font="font13" id="p1_t42" reading_order_no="40" segment_no="18" tag_type="text">inhibitor (SLPI) and survivin.</text>
<text top="583" left="57" width="240" height="8" font="font12" id="p1_t43" reading_order_no="41" segment_no="22" tag_type="text">Methods We employed E1-deleted Ads that express the</text>
<text top="593" left="57" width="240" height="8" font="font13" id="p1_t44" reading_order_no="42" segment_no="22" tag_type="text">reporter gene luciferase under the control of the promoters of</text>
<text top="404" left="315" width="240" height="8" font="font13" id="p1_t45" reading_order_no="43" segment_no="19" tag_type="text">interest. We evaluated this class of vectors in various</text>
<text top="415" left="315" width="240" height="8" font="font13" id="p1_t46" reading_order_no="44" segment_no="19" tag_type="text">established breast cancer cell lines, primary breast cancer cells</text>
<text top="425" left="315" width="241" height="8" font="font13" id="p1_t47" reading_order_no="45" segment_no="19" tag_type="text">and finally in the most stringent preclinical available substrate</text>
<text top="436" left="315" width="240" height="8" font="font13" id="p1_t48" reading_order_no="46" segment_no="19" tag_type="text">system, constituted by precision cut tissue slices of human</text>
<text top="446" left="315" width="89" height="8" font="font13" id="p1_t49" reading_order_no="47" segment_no="19" tag_type="text">breast cancer and liver.</text>
<text top="472" left="315" width="241" height="8" font="font12" id="p1_t50" reading_order_no="48" segment_no="20" tag_type="text">Results Overall, the CXCR4 promoter exhibited the highest</text>
<text top="483" left="315" width="240" height="8" font="font13" id="p1_t51" reading_order_no="49" segment_no="20" tag_type="text">luciferase activity in breast cancer cell lines, primary breast</text>
<text top="493" left="315" width="240" height="8" font="font13" id="p1_t52" reading_order_no="50" segment_no="20" tag_type="text">cancer cells and breast cancer tissue slices. Importantly, the</text>
<text top="504" left="315" width="240" height="8" font="font13" id="p1_t53" reading_order_no="51" segment_no="20" tag_type="text">CXCR4 promoter displayed a very low activity in human primary<i>Breast Cancer Research</i></text>
<text top="514" left="315" width="240" height="8" font="font13" id="p1_t54" reading_order_no="52" segment_no="20" tag_type="text">fibroblasts and human liver tissue slices. Interestingly, gene</text>
<text top="525" left="315" width="240" height="8" font="font13" id="p1_t55" reading_order_no="53" segment_no="20" tag_type="text">expression profiles correlated with the promoter activities both<b>7</b></text>
<text top="535" left="315" width="221" height="8" font="font13" id="p1_t56" reading_order_no="54" segment_no="20" tag_type="text">in breast cancer cell lines and primary breast cancer cells.</text>
<text top="562" left="315" width="241" height="8" font="font12" id="p1_t57" reading_order_no="55" segment_no="21" tag_type="text">Conclusion These data suggest that the CXCR4 promoter has<a href="http://breast-cancer-research.com/content/7/6/R1141">This article is online at: http://breast-cancer-research.com/content/7/6/R1141</a></text>
<text top="572" left="315" width="240" height="8" font="font13" id="p1_t58" reading_order_no="56" segment_no="21" tag_type="text">an ideal 'breast cancer-on/liver-off' profile, and could, therefore,</text>
<text top="583" left="315" width="240" height="8" font="font13" id="p1_t59" reading_order_no="57" segment_no="21" tag_type="text">be a powerful tool in Ad vector based gene therapy or<i> et al</i></text>
<text top="593" left="315" width="160" height="8" font="font13" id="p1_t60" reading_order_no="58" segment_no="21" tag_type="text">virotherapy of the carcinoma of the breast.</text>
<text top="627" left="57" width="64" height="10" font="font11" id="p1_t61" reading_order_no="59" segment_no="23" tag_type="title">Introduction<a href="http://creativecommons.org/licenses/by/2.0"> (http://creativecommons.org/licenses/by/2.0), </a></text>
<text top="639" left="57" width="240" height="9" font="font13" id="p1_t62" reading_order_no="60" segment_no="25" tag_type="text">Breast cancer is the most common cancer in the world. It</text>
<text top="650" left="57" width="240" height="9" font="font13" id="p1_t63" reading_order_no="61" segment_no="25" tag_type="text">affects 1 in 9 women in the United States where 46,000<b>Abstract</b></text>
<text top="662" left="57" width="240" height="9" font="font13" id="p1_t64" reading_order_no="62" segment_no="25" tag_type="text">women die from breast cancer each year despite early<b>Introduction</b></text>
<text top="674" left="57" width="240" height="9" font="font13" id="p1_t65" reading_order_no="63" segment_no="25" tag_type="text">detection methods and advanced conventional treatments [1].</text>
<text top="627" left="315" width="240" height="9" font="font13" id="p1_t66" reading_order_no="64" segment_no="24" tag_type="text">Clearly, novel therapies for breast cancer are required. Gene</text>
<text top="639" left="315" width="240" height="9" font="font13" id="p1_t67" reading_order_no="65" segment_no="24" tag_type="text">therapy and virotherapy constitute a novel therapeutic</text>
<text top="650" left="315" width="240" height="9" font="font13" id="p1_t68" reading_order_no="66" segment_no="24" tag_type="text">approach for the treatment of advanced, recurrent and meta-</text>
<text top="662" left="315" width="240" height="9" font="font13" id="p1_t69" reading_order_no="67" segment_no="24" tag_type="text">static breast cancer. In gene therapy approaches, a therapeu-</text>
<text top="674" left="315" width="240" height="9" font="font13" id="p1_t70" reading_order_no="68" segment_no="24" tag_type="text">tic gene for mutation compensation, immunopotentiation, or</text>
<text top="695" left="57" width="499" height="7" font="font3" id="p1_t71" reading_order_no="69" segment_no="26" tag_type="footnote">Ad = adenovirus; BSA = bovine serum albumin; CAR Coxsackie-Adenovirus-Receptor; CMV = cytomegalovirus; Cox = cyclooxygenase; CXCR4 =</text>
<text top="703" left="57" width="499" height="10" font="font15" id="p1_t72" reading_order_no="70" segment_no="26" tag_type="footnote">α -chemokine SDF-1 receptor; DAPI = 4',6-diamidino-2-phenylindole dihydrochloride; EGP = epithelial glycoprotein; FCS = fetal calf serum; GAPDH</text>
<text top="714" left="57" width="499" height="7" font="font3" id="p1_t73" reading_order_no="71" segment_no="26" tag_type="footnote">= glyceraldehyde-3-phosphate dehydrogenase; MOI = multiplicity of infection; PBS = phosphate-buffered saline; PCR = polymerase chain reaction;</text>
<text top="724" left="57" width="499" height="7" font="font3" id="p1_t74" reading_order_no="72" segment_no="26" tag_type="footnote">SLPI = secretory leukoprotease inhibitor; TSP = tissue specific promoter; UAB = University of Alabama at Birmingham; UW = University of Wiscon-</text>
<text top="733" left="57" width="14" height="7" font="font3" id="p1_t75" reading_order_no="73" segment_no="26" tag_type="footnote">sin.</text>
</page>
</pdf2xml>
